{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:18:23Z","timestamp":1785838703265,"version":"3.56.0"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To study whether there is an association between body mass index (BMI) category and survival of various tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients in a real-life longitudinal international registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from 5230 patients with RA starting treatment with any TNFi were selected from the METEOR registry. Patients were divided into six BMI categories: 3.7% underweight, BMI&lt;18.5 kg\/m<jats:sup>2<\/jats:sup>; 46% normal weight, BMI 18.5\u201325 kg\/m<jats:sup>2<\/jats:sup>; 32% pre-obesity, BMI 25\u201330 kg\/m<jats:sup>2<\/jats:sup>; 13% obesity class I, BMI 30\u201335 kg\/m<jats:sup>2<\/jats:sup>; 3.4% obesity class II, BMI 35\u201340 kg\/m<jats:sup>2<\/jats:sup>; and 1.6% obesity class III, BMI &gt;40 kg\/m<jats:sup>2<\/jats:sup>. Time on treatment in the different BMI categories was compared for all TNFi combined and for the infliximab, adalimumab and etanercept separately, using Kaplan\u2013Meier curves and Cox regression analyses. Cox regression analyses were adjusted for potential confounders, with follow-up censored at 5000\u00a0days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients in obesity class II (HR 1.28, 95% CI 1.06 to 1.54) and III (HR 1.67, 95% CI 1.29 to 2.18) and underweight patients (HR 1.30, 95% CI 1.07 to 1.58) showed statistically significantly shorter TNFi survival than normal weight patients. The effect in underweight patients was strongest for infliximab (HR 1.82, 95% CI 1.20 to 2.76), the effect in overweight patients was strongest for infliximab (category II (HR 1.49, 95% CI 0.98 to 2.26); category III (HR 1.46, 95% CI 0.79 to 2.71)) and etanercept (category II (HR 1.27 95% CI 0.98 to 1.65); category III (HR 1.79, 95% CI 1.25 to 2.55)). No significant effect modification from reported pain was found.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Both underweight and overweight patients discontinued TNFi treatment earlier than normal weight patients, without evidence of reported pain as the main determinant. It remains uncertain what determines TNFi survival in individual patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001203","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T17:51:57Z","timestamp":1591465917000},"page":"e001203","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Body mass index and treatment survival in patients with RA starting treatment with TNF\u03b1-inhibitors: long-term follow-up in the real-life METEOR registry"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"first","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vega-Morales","sequence":"additional","affiliation":[{"name":"Universidad Autonoma de Nuevo Leon, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"De Buck","sequence":"additional","affiliation":[{"name":"Rheumatology, Haaglanden Medical Center, The Hague, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Murphy","sequence":"additional","affiliation":[{"name":"University Hospital Wishaw, Wishaw, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Salomon Escoto","sequence":"additional","affiliation":[{"name":"Rheumatology, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-7520","authenticated-orcid":false,"given":"Tom W J","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"2025090312513886000_6.2.e001203.1","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet (London, England) 2017; 2627\u201342."},{"key":"2025090312513886000_6.2.e001203.2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet (London, England)"},{"key":"2025090312513886000_6.2.e001203.3","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/acr.23213","article-title":"Population-based study of changes in arthritis prevalence and arthritis risk factors over time: generational differences and the role of obesity","volume":"69","author":"Badley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312513886000_6.2.e001203.4","doi-asserted-by":"publisher","DOI":"10.1038\/nri1937"},{"key":"2025090312513886000_6.2.e001203.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.232"},{"key":"2025090312513886000_6.2.e001203.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.30136"},{"key":"2025090312513886000_6.2.e001203.7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312513886000_6.2.e001203.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025090312513886000_6.2.e001203.9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"2025090312513886000_6.2.e001203.10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw079"},{"key":"2025090312513886000_6.2.e001203.11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/acr.21978","article-title":"Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients","volume":"65","author":"Heimans","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312513886000_6.2.e001203.12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","article-title":"Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients","volume":"82","author":"Iannone","year":"2015","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"2025090312513886000_6.2.e001203.13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-017-1484-9","article-title":"Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: Results of the PRESERVE trial","volume":"20","author":"Smolen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312513886000_6.2.e001203.14","doi-asserted-by":"crossref","unstructured":"Rodrigues AM , J.E. R , C S , et al. Obesity is a risk factor for worse treatment response in rheumatoid arthritis patients - results from reuma.pt. Ann Rheumatic Dis Conf: Eur Works Rheumatol Res 2014;73.","DOI":"10.1136\/annrheumdis-2013-205124.1"},{"key":"2025090312513886000_6.2.e001203.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171232"},{"key":"2025090312513886000_6.2.e001203.16","first-page":"478","article-title":"Body mass index and response to infliximab in rheumatoid arthritis","volume":"33","author":"Ottaviani","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312513886000_6.2.e001203.17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-016-3220-2","article-title":"No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study","volume":"35","author":"Kim","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312513886000_6.2.e001203.18","first-page":"422","article-title":"Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis","volume":"37","author":"McCulley","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312513886000_6.2.e001203.19","unstructured":"BMI classification. Available http:\/\/www.assessmentpsychology.com\/icbmi.htm"},{"key":"2025090312513886000_6.2.e001203.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186575","article-title":"Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with infliximab","volume":"12","author":"Scaldaferri","year":"2017","journal-title":"PLoS One"},{"key":"2025090312513886000_6.2.e001203.21","first-page":"S87","article-title":"Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives","volume":"34","author":"Bergstra","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312513886000_6.2.e001203.22","unstructured":"Body mass index \u2013 BMI. Available www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi"},{"key":"2025090312513886000_6.2.e001203.23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jpain.2006.12.003","article-title":"Comorbidity of obesity and pain in a general population: results from the Southern Pain Prevalence Study","volume":"8","author":"Hitt","year":"2007","journal-title":"J Pain: Offic J Amer Pain Soc"},{"key":"2025090312513886000_6.2.e001203.24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(80)91537-8","article-title":"Pain and obesity","volume":"1","author":"Pradalier","year":"1980","journal-title":"Lancet (London, England)"},{"key":"2025090312513886000_6.2.e001203.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1885-z"},{"key":"2025090312513886000_6.2.e001203.26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.21710","article-title":"Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset","volume":"65","author":"Ajeganova","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312513886000_6.2.e001203.27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MEG.0000000000000544","article-title":"Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels","volume":"28","author":"Bond","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025090312513886000_6.2.e001203.28","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/acr.23229","article-title":"Impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis","volume":"69","author":"George","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312513886000_6.2.e001203.29","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RHU.0000000000000799","article-title":"Obesity impacts swelling of ankle and foot joints in early rheumatoid arthritis patients","volume":"25","author":"Ranganath","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2025090312513886000_6.2.e001203.30","doi-asserted-by":"publisher","DOI":"10.2165\/11318100-000000000-00000"},{"key":"2025090312513886000_6.2.e001203.31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/BOR.0000000000000479","article-title":"Epidemiology of osteoarthritis: literature update","volume":"30","author":"Vina","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312513886000_6.2.e001203.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket433"},{"key":"2025090312513886000_6.2.e001203.33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","article-title":"Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis","volume":"19","author":"Micheroli","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312513886000_6.2.e001203.34","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32835d1f15"},{"key":"2025090312513886000_6.2.e001203.35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.14552","article-title":"Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry","volume":"175","author":"Zweegers","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025090312513886000_6.2.e001203.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"2025090312513886000_6.2.e001203.37","doi-asserted-by":"publisher","DOI":"10.1159\/000156599"},{"key":"2025090312513886000_6.2.e001203.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:04Z","timestamp":1756929124000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,6]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/rmdopen-2020-001203"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001203","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}